SUBSCRIBE
IQVIA Blog Digest
For all the latest industry insights, please subscribe to the IQVIA U.S. blog digest.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
WHO WE HELP
-
Pharmaceutical Manufacturers
-
Emerging Biopharma
-
MedTech
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MorePharmaceutical Manufacturers
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsMedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover More
Medical Specialty and Patient Advocacy
Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Explore NowU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSBlog
Rethink patient support with in-home phlebotomy
Jan 29, 2021
Non-adherence to prescribed therapy has long been a serious issue that may lead to detrimental consequences for patient outcomes. Indeed, an alarming number of patients with chronic conditions never even initiate their prescribed therapy. For instance, up to half of patients diagnosed with hyperlipidemia and nearly a third of those with HIV don’t fill their prescriptions,1 while those that do, too often discontinue use in the first year of treatment.
The need to assess patients’ lab values prior to initiating therapy, or to monitor them over the course of therapy, is one more hurdle that exacerbates an already intractable problem. Traveling to a clinic to have blood drawn deters many patients from initiating and adhering to their therapy in the best of times, but now, this is especially onerous due to the impact of the COVID-19 pandemic as individuals may be required to shelter in place.
Accessing in-home phlebotomy services, frequently used in decentralized clinical trials, is one solution to make it easier for patients during the pandemic and beyond.
IQVIA’s patient-centric approach
With IQVIA’s latest in-home phlebotomy services, nurses or phlebotomists can easily be deployed to support patients who are prescribed drugs for which blood draws or laboratory workups are requisite clinical standards. Our in-home phlebotomy services are structured to connect the multiple parties involved in the blood collection and analysis process.
- First, the pharmaceutical company contracts with IQVIA, for either a standalone service, or as part of a more comprehensive Patient Support Program. Then, through marketing campaigns, the pharmaceutical company introduces the program to healthcare providers as an available service for patients going on therapy.
- The prescribing physician makes a treatment decision and subsequently enrolls the patient in the program.
- A nurse/phlebotomist is assigned to the patient based on geography and arranges a blood draw according to the patient’s availability. Then, the nurse or certified phlebotomist visits the patient’s home and conducts the prescribed blood draw.
- The prescriber is notified when the blood draw is scheduled and completed.
- The sample is sent either to the prescriber or directly to a lab for testing. In some cases, IQVIA can facilitate the lab analysis.
- Lastly, the results are communicated to the HCP and the HCP discusses with the patient via the prescribing physician.
Ensuring a compliant process
The IQVIA program is designed to support specific prescriptions and is not a general phlebotomy service that physicians can request outside of the contract parameters; only the labs that are in the PI are to be ordered. To ensure that its service complies with all regulations and medical standards, it is structured so that
- Patient enrollment in the program is driven by a prescription, which follows the treatment decision.
- There is a firewall between the nurse/phlebotomist and sales roles.
- The nurse/phlebotomist never discusses patient care or prescribing information with the patient.
- Lab results are provided to the prescriber and via the prescriber, to the patient.
By utilizing IQVIA’s remote phlebotomy services, pharmaceutical companies can better support prescription adherence by ensuring patients receive and continue with their prescribed therapy by removing the laboratory access barrier. To learn more, contact us.
1 Final % claims not paid (1H20), IQVIA LAAD Claims Data.
Learn how you can overcome treatment barriers with a Clinical Network
Read the facts about deploying remote phlebotomy services to help patients start — and stay — on therapies.